(Q37689997)

22 August 2017

1 reference

title

Ovarian cancer creates a suppressive microenvironment to escape immune elimination (English)

1 reference

22 August 2017

1 reference

3

1 reference

22 August 2017

4

1 reference

22 August 2017

Refika Yigit

1

1 reference

22 August 2017

Leon F A G Massuger

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

9 February 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

117

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

366-372

1 reference

Estimates of the cancer incidence and mortality in Europe in 2006.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

7 January 2021

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Immune therapy for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Overexpression of inhibitor of DNA-binding (ID)-1 protein related to angiogenesis in tumor advancement of ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Adoptive cell transfer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Cancer regression in patients after transfer of genetically engineered lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Targeting antigens to dendritic cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Immune suppression in the tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Transforming growth factor-beta regulation of immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

TGF beta inhibition for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Interleukin-10 and the interleukin-10 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Interleukin-10: a cytokine used by tumors to escape immunosurveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Tumor-induced immune dysfunction: the macrophage connection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Tregs and rethinking cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Immunological ignorance of solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Tumor dormancy and immunoescape.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Overexpression of cyclooxygenase-2 correlates with tumor angiogenesis in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Myeloid suppressor cells regulate the adaptive immune response to cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Clonal expansion of T cells that are specific for autologous ovarian tumor among tumor-infiltrating T cells in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Development and function of naturally occurring CD4+CD25+ regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Natural versus adaptive regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Expression of the co-stimulatory molecule CD40 on melanoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Interferon-gamma and tumor necrosis factor-alpha treatment of ex vivo human carcinoma cells potentiates their interaction with allogeneic lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

CTLA-4 is a second receptor for the B cell activation antigen B7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Role of transforming growth factor-beta superfamily signaling pathways in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Transforming growth factor-beta: recent advances on its role in immune tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Transforming growth factor β and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Role of vascular leukocytes in ovarian cancer neovascularization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Modulation of tryptophan catabolism by regulatory T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.019

10.1016/J.YGYNO.2010.01.019

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference